An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Inc
- 31 May 2017 Results (n= 452) assessing optimal lenvatinib dose based on population PK and exposure-response analysis using using pooled data from NCT00946153, NCT00121719, NCT00121680, NCT00280397, NCT01268293 and other 8 phase 1 studies in healthy adults, published in the Journal of Clinical Pharmacology
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.